Drug intelligence / Profile preview

JNJ-26528398

Development stage: Phase 1
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Oral

Overview

JNJ-26528398 is an orally administered small molecule anti-inflammatory agent developed by Johnson & Johnson Pharmaceutical Research & Development and Janssen Research & Development. It acts as a tumor necrosis factor alpha (TNF-α) modulator, functioning as an immunomodulator to reduce inflammation. The drug was investigated primarily for inflammatory conditions, including acute sinusitis and other respiratory or otorhinolaryngologic diseases. Its highest reported clinical development phase was Phase 1, with no further development reported after initial trials in volunteers[1][2].

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on JNJ-26528398.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-26528398.

Explore the full profile